Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study

Bulut, Esra AtesAlak, Zehra Yagmur SahinDokuzlar, OzgeKocyigit, Suleyman EmreSOYSAL, PINARSmith, LeeIŞIK, AHMET TURAN2020-06-052020-06-052020-05-01Bulut E. A. , Alak Z. Y. S. , Dokuzlar O., Kocyigit S. E. , SOYSAL P., Smith L., IŞIK A. T. , -Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study-, ARCHIVES OF GERONTOLOGY AND GERIATRICS, cilt.88, 2020https://hdl.handle.net/20.500.12645/18044Aims: Type 2 Diabetes Mellitus(DM) is a well-known risk factor for cognitive impairment. Recent evidences suggest that Dipeptidyl peptidase-4(DPP-4) inhibitors might have neuroprotective effects. Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM.enCognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up studyArticleWOS:0005345401000148507867252510.1016/j.archger.2020.10401332014700